Latest BAKER BROS. ADVISORS LP Stock Portfolio
$7.83Billion– No. of Holdings #93
BAKER BROS. ADVISORS LP Performance:
2024 Q2: -3.37%YTD: -10.69%2023: -0.24%
Performance for 2024 Q2 is -3.37%, and YTD is -10.69%, and 2023 is -0.24%.
About BAKER BROS. ADVISORS LP and 13F Hedge Fund Stock Holdings
BAKER BROS. ADVISORS LP is a hedge fund based in NEW YORK, NY. On 24-Mar-2023, the fund reported that it had an AUM (Regulated Assets under Management) of $23.2 Billions. In it's latest 13F Holdings report, BAKER BROS. ADVISORS LP reported an equity portfolio of $7.8 Billions as of 30 Jun, 2024.
The top stock holdings of BAKER BROS. ADVISORS LP are INCY, BGNE, ACAD. The fund has invested 23.8% of it's portfolio in INCYTE CORPORATION and 19.3% of portfolio in BEIGENE, LTD.
The fund managers got completely rid off KINIKSA PHARMACEUTICALS, LTD. (KNSA), DBV TECHNOLOGIES S.A. (DBVT) and HOOKIPA PHARMA INC. (HOOK) stocks. They significantly reduced their stock positions in BIOCRYST PHARMACEUTICALS, INC. (BCRX), ADAPTIMMUNE THERAPEUTICS PLC (ADAP) and AEROVATE THERAPEUTICS, INC. (AVTE). BAKER BROS. ADVISORS LP opened new stock positions in SUMMIT THERAPEUTICS INC. (SMMT), ALKERMES PLC (ALKS) and KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC. The fund showed a lot of confidence in some stocks as they added substantially to INSMED INCORPORATED (INSM), KALA BIO, INC. (KALA) and GENERATION BIO CO. (GBIO).
The top stock holdings of BAKER BROS. ADVISORS LP are INCY, BGNE, ACAD. The fund has invested 23.8% of it's portfolio in INCYTE CORPORATION and 19.3% of portfolio in BEIGENE, LTD.
The fund managers got completely rid off KINIKSA PHARMACEUTICALS, LTD. (KNSA), DBV TECHNOLOGIES S.A. (DBVT) and HOOKIPA PHARMA INC. (HOOK) stocks. They significantly reduced their stock positions in BIOCRYST PHARMACEUTICALS, INC. (BCRX), ADAPTIMMUNE THERAPEUTICS PLC (ADAP) and AEROVATE THERAPEUTICS, INC. (AVTE). BAKER BROS. ADVISORS LP opened new stock positions in SUMMIT THERAPEUTICS INC. (SMMT), ALKERMES PLC (ALKS) and KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC. The fund showed a lot of confidence in some stocks as they added substantially to INSMED INCORPORATED (INSM), KALA BIO, INC. (KALA) and GENERATION BIO CO. (GBIO).
BAKER BROS. ADVISORS LP Equity Portfolio Value
Last Reported on: 14 Aug, 2024
BAKER BROS. ADVISORS LP Annual Return Estimates Vs S&P 500
Our best estimate is that BAKER BROS. ADVISORS LP made a return of -3.37% in the last quarter. In trailing 12 months, it's portfolio return was -3.96%.
New Buys
| Ticker | $ Bought |
|---|---|
| summit therapeutics inc. | 181,133,000 |
| alkermes plc | 100,780,000 |
| insmed incorporated | 90,413,500 |
| insmed incorporated | 56,192,300 |
| kiniksa pharmaceuticals international, plc | 52,618,100 |
| alumis inc. | 20,781,200 |
| merus n.v. | 17,751,000 |
| dbv technologies s.a. | 5,853,010 |
New stocks bought by BAKER BROS. ADVISORS LP
Additions
| Ticker | % Inc. |
|---|---|
| insmed incorporated | 942 |
| kala bio, inc. | 234 |
| generation bio co. | 225 |
| protara therapeutics, inc. | 168 |
| dyne therapeutics, inc. | 135 |
| bicycle therapeutics plc | 90.17 |
| fate therapeutics, inc. | 64.88 |
| neumora therapeutics, inc. | 63.22 |
Additions to existing portfolio by BAKER BROS. ADVISORS LP
Reductions
| Ticker | % Reduced |
|---|---|
| biocryst pharmaceuticals, inc. | -99.25 |
| adaptimmune therapeutics plc | -78.27 |
| aerovate therapeutics, inc. | -62.57 |
| roivant sciences ltd. | -62.25 |
| akero therapeutics, inc. | -59.57 |
| sage therapeutics, inc. | -58.00 |
| cerevel therapeutics holdings, inc. | -57.28 |
| argenx se | -26.00 |
BAKER BROS. ADVISORS LP reduced stake in above stock
Sold off
| Ticker | $ Sold |
|---|---|
| dbv technologies s.a. | -10,947,500 |
| kiniksa pharmaceuticals, ltd. | -55,433,000 |
| hookipa pharma inc. | -5,787,240 |
| mural oncology plc | -1,088,040 |
| perspective therapeutics, inc. | -178,247 |
| 4d molecular therapeutics, inc. | -3,186,000 |
| alpine immune sciences, inc. | -3,233,750 |
| cabaletta bio, inc. | -227,427 |
BAKER BROS. ADVISORS LP got rid off the above stocks
Sector Distribution
BAKER BROS. ADVISORS LP has about 96.7% of it's holdings in Healthcare sector.
| Sector | % |
|---|---|
| Healthcare | 96.7 |
| Others | 3.3 |
Market Cap. Distribution
BAKER BROS. ADVISORS LP has about 47% of it's portfolio invested in the large-cap and mega-cap stocks.
| Category | % |
|---|---|
| MID-CAP | 32.2 |
| LARGE-CAP | 27.4 |
| MEGA-CAP | 19.6 |
| SMALL-CAP | 14.7 |
| UNALLOCATED | 4 |
| MICRO-CAP | 1.9 |
Stocks belong to which Index?
About 69.5% of the stocks held by BAKER BROS. ADVISORS LP either belong to S&P 500 or RUSSELL 2000 index.
| Index | % |
|---|---|
| RUSSELL 2000 | 45.2 |
| Others | 30.5 |
| S&P 500 | 24.3 |
BAKER BROS. ADVISORS LP Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of BAKER BROS. ADVISORS LP
BAKER BROS. ADVISORS LP has 93 stocks in it's portfolio. About 76.3% of the portfolio is in top 10 stocks. BGNE proved to be the most loss making stock for the portfolio. INSM was the most profitable stock for BAKER BROS. ADVISORS LP last quarter.
Last Reported on: 14 Aug, 2024| Ticker | Namesorted ascending | % Portfolio | Shares Held | $ Value | Type | % Change | Options | |
|---|---|---|---|---|---|---|---|---|
| ABCL | abcellera biologics inc. | 1.04 | 27,525,600 | 81,475,900 | unchanged | 0.00 | ||
| ACAD | acadia pharmaceuticals inc. | 8.90 | 42,877,900 | 696,766,000 | added | 0.03 | ||
| ACHL | achilles therapeutics plc | 0.01 | 1,108,770 | 903,645 | reduced | -8.27 | ||
| ADAP | adaptimmune therapeutics plc | 0.03 | 2,343,700 | 2,284,870 | reduced | -78.27 | ||
| AKRO | akero therapeutics, inc. | 0.33 | 1,097,080 | 25,737,500 | reduced | -59.57 | ||
| ALEC | alector, inc. | 0.05 | 927,264 | 4,209,780 | new | |||
| ALGS | aligos therapeutics, inc. | 0.01 | 2,076,400 | 726,740 | unchanged | 0.00 | ||
| ALKS | alkermes plc | 1.29 | 4,181,750 | 100,780,000 | new | |||
| ALPN | alpine immune sciences, inc. | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| ARCT | arcturus therapeutics holdings inc. | 0.05 | 151,329 | 3,684,860 | new | |||
| ATHA | athira pharma, inc. | 0.11 | 3,153,810 | 8,357,590 | unchanged | 0.00 | ||
| AVTE | aerovate therapeutics, inc. | 0.01 | 628,939 | 1,044,040 | reduced | -62.57 | ||
| BCRX | biocryst pharmaceuticals, inc. | 0.01 | 75,778 | 468,308 | reduced | -99.25 | ||
| BCYC | bicycle therapeutics plc | 2.43 | 9,399,960 | 190,255,000 | added | 90.17 | ||
| BGNE | beigene, ltd. | 19.27 | 10,568,900 | 1,507,860,000 | unchanged | 0.00 | ||
| BMEA | biomea fusion, inc. | 0.12 | 2,108,950 | 9,490,270 | unchanged | 0.00 | ||
| CABA | cabaletta bio, inc. | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| CELC | celcuity inc. | 0.39 | 1,874,980 | 30,712,100 | added | 20.77 | ||
| CERE | cerevel therapeutics holdings, inc. | 0.36 | 683,588 | 27,951,900 | reduced | -57.28 | ||
| CERS | cerus corporation | 0.44 | 19,477,300 | 34,280,100 | unchanged | 0.00 | ||